162 related articles for article (PubMed ID: 31244092)
1. Gain-of-Function SHP2 E76Q Mutant Rescuing Autoinhibition Mechanism Associated with Juvenile Myelomonocytic Leukemia.
Rehman AU; Rafiq H; Rahman MU; Li J; Liu H; Luo S; Arshad T; Wadood A; Chen HF
J Chem Inf Model; 2019 Jul; 59(7):3229-3239. PubMed ID: 31244092
[TBL] [Abstract][Full Text] [Related]
2. Exploring the effect of E76K mutation on SHP2 cause gain-of-function activity by a molecular dynamics study.
Li WY; Wei HY; Sun YZ; Zhou H; Ma Y; Wang RL
J Cell Biochem; 2018 Dec; 119(12):9941-9956. PubMed ID: 30129165
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
Elife; 2022 May; 11():. PubMed ID: 35535491
[TBL] [Abstract][Full Text] [Related]
4. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
[TBL] [Abstract][Full Text] [Related]
5. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
[TBL] [Abstract][Full Text] [Related]
6. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.
Calligari P; Santucci V; Stella L; Bocchinfuso G
Comput Struct Biotechnol J; 2021; 19():6125-6139. PubMed ID: 34900129
[TBL] [Abstract][Full Text] [Related]
7. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics.
Wang RR; Ma Y; Du S; Li WY; Sun YZ; Zhou H; Wang RL
Comput Biol Chem; 2019 Feb; 78():133-143. PubMed ID: 30508783
[TBL] [Abstract][Full Text] [Related]
8. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
[TBL] [Abstract][Full Text] [Related]
9. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2
Zhou L; Feng Y; Ma YC; Zhang Z; Wu JW; Du S; Li WY; Lu XH; Ma Y; Wang RL
J Mol Graph Model; 2021 Mar; 103():107807. PubMed ID: 33338846
[TBL] [Abstract][Full Text] [Related]
10. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study.
Li HL; Ma Y; Zheng CJ; Jin WY; Liu WS; Wang RL
J Biomol Struct Dyn; 2018 Nov; 36(14):3856-3868. PubMed ID: 29125030
[TBL] [Abstract][Full Text] [Related]
11. An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.
Anselmi M; Hub JS
Sci Rep; 2020 Oct; 10(1):18530. PubMed ID: 33116231
[TBL] [Abstract][Full Text] [Related]
12. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
He C; Peng Z; Zhang D; Guo Y; Liang T; Zhao Y; Yu L; Zhang Q; Chang Z; Xiao Y; Li N; Xue H; Wu S; Zhao ZJ; Zhang C; Chen Y
Biochem Pharmacol; 2023 Jul; 213():115588. PubMed ID: 37187274
[TBL] [Abstract][Full Text] [Related]
14. Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
Cai Z; Zhang C; Kotzin JJ; Williams A; Henao-Mejia J; Kapur R
Blood Adv; 2020 Jul; 4(14):3246-3251. PubMed ID: 32697817
[TBL] [Abstract][Full Text] [Related]
15. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
[TBL] [Abstract][Full Text] [Related]
17. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
[TBL] [Abstract][Full Text] [Related]
18. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Wu J; Li W; Zheng Z; Lu X; Zhang H; Ma Y; Wang R
J Biomol Struct Dyn; 2021 Mar; 39(4):1174-1188. PubMed ID: 32036779
[TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]